Table 2.
Treatment groups defined by Adjuvant! Online (from ref. 1)
| Endocrine therapy regimens | Examples |
|---|---|
| • Tamoxifen (Tam) for 5 years | |
| • Aromatase inhibitor (AI) for 5 years | |
| • Tam for 2–3 years followed by AI for 2–3 years | |
| •Ovarian ablation | |
| •Ovarian ablation plus Tam (or another hormonal agent)a | |
|
| |
| Chemotherapy regimens | |
|
| |
| • 6 cycles of cyclophosphamide( C), methotrexate (M), 5-fluorouracil (F) [CMF*6] (Overview 2000) | |
| • Anthracycline-based (Overview 2000) | |
| • 1st generation regimen (G1)b (Shown to be equal to CMF or to be better than no therapy to a degree similar to that expected for CMF.) CA*4, CMF*6, FE(50)C*6 |
Four cycles of C, doxorubicin (A) [CA*4] CMF * 6 F, epirubicin (E)(50), C [FE(50)C*6] |
| • 2nd generation regimens (G2) (Superior to G1, assumes15% – 20% better relative efficacy than CMF.) | CAF *6 FEC*6 FE(100)C*6 FAC*6 CA*4 followed by 4 cycles of taxanes (T) given every 3 weeks [CA*4 then T*4 (q3w)] |
| CA*4 then T*4 (q3w) Anthracycline-based regimen with more than 4 cycles and more than two agents |
|
| • 3rd generation regimens (G3) (15% – 20% better than G2 which are 15% – 20% better than G1–this makes G3 regimens 35% better than CMF) | TAC*6 FE(100)C*3 followed by 3 cycles of (D) dose-dense CA*4 T *4 (all ) |
| • Chemotherapy benefit adjusted by user. | TAC FEC*3+docetaxel (D)*3 CA(Q2W)*4 + Taxol(Q2W)*4 FEC*4+T *8 (Q1W) |
a
Regimen matching the IBCSG Trial 11-93 prescribed endocrine therapy
b
Regimen matching the IBCSG Trial 11-93 prescribed chemotherapy